BVS — BIOVENTUS INC (Healthcare >> Medical Devices)
BVS FAQ
What is BVS's P/E ratio?
BIOVENTUS INC (BVS) currently trades at a P/E ratio of 20.69.
What is BVS's ROE?
BIOVENTUS INC reports a Return on Equity (ROE) of 15.08%.
What is BVS's dividend yield?
BIOVENTUS INC offers a dividend yield of 0.00%.
What is BVS's Deepscope Quality Score?
Deepscope rates BVS's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BVS?
Deepscope's AI Timing Score for BVS is 28 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BVS belong to?
BIOVENTUS INC is classified under the Healthcare >> Medical Devices sector on the NASDAQ exchange.
|
USD 9.04
Price
0.34
(3.91%)
Day Change
|
|
|---|
BVS, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
2002
|
| Magic Formula Rank by ROE |
2002
|
| Magic Formula Rank by ROIC |
1420
|
| Price | 9.04 |
| PBV / Sector |
2.52 / 7.50
|
| Earning Per Share | 0.44 |
| PE / Sector |
20.69 / 29.01
|
| PEG or PE/Growth / Sector |
-0.25 / 0.39
|
| Average 1M Daily Value |
6.33 M
|
| Average 1W Daily Value |
8.20 M
|
| Timing Factors |
|
42% |
| Financial Health |
|
43% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:28 |
| Symbol | BVS |
| Name | BIOVENTUS INC |
| Sector | Healthcare >> Medical Devices |
| Market | NASDAQ |
| Listed Shares | 67.75 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 589.41 / 18,389.26 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 4721 Emperor Boulevard, Durham, NC, United States, 27703
Phone: 919 474 6700
Website: https://www.bioventus.com
Employees: 940
Sector: Healthcare >> Medical Devices
Description: Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
Google